# NCT03289962 (NCT03289962)

> A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03289962
- Phase: PHASE1
- Status: COMPLETED
- Sponsor: Genentech, Inc.
- Conditions: Melanoma; Non-Small Cell Lung Cancer; Bladder Cancer; Colorectal Cancer; Triple Negative Breast Cancer; Renal Cancer; Head and Neck Cancer; Other Solid Cancers
- Interventions: Autogene cevumeran; Atezolizumab
- Enrollment: 273
- Primary outcome: Percentage of Participants with Dose-Limiting Toxicities (DLTs)
- Primary outcome: MTD/Recommended Phase 2 Dose (RP2D) of Autogene Cevumeran
- Primary outcome: Percentage of Participants with Adverse Events (AEs)
- Primary outcome: Percentage of Participants with Immune-Mediated Adverse Events (imAEs)
- Primary outcome: Percentage of Participants by Number of Treatment Cycles Received
- Primary outcome: Dose Intensity of Autogene Cevumeran
- Primary outcome: Change from Baseline in Targeted Vital Signs
- Primary outcome: Change from Baseline in Targeted Clinical Laboratory Test Results
- Primary outcome: Change from Baseline in ECGs

## Indexed commentary on NCT03289962 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct03289962